Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04409639 · ClinicalTrials.gov registry record · Phase 2
Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
A Phase 2 study of Chronic Myelomonocytic Leukemia (CMML), sponsored by University of Utah.
- Active
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 3
- Study locations
NCT04409639 is a Phase 2 study of Chronic Myelomonocytic Leukemia (CMML) that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 29 participants, below the 161-participant average among 6 other Chronic Myelomonocytic Leukemia (CMML) trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT04409639, a Phase 2 study of Chronic Myelomonocytic Leukemia (CMML), is active but no longer recruiting, sponsored by University of Utah.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an open-label, nonrandomized phase 2 trial to assess the efficacy of cobimetinib in RAS pathway activated CMML. All eligible patients will be treated daily with cobimetinib in 28-day cycles. Cobimetinib will be administered for three weeks followed by a one week break prior to the start of the following cycle. Patients will remain on study therapy until treatment discontinuation criteria is met.
Conditions Studied
Interventions
- DRUG Cobimetinib
Study Locations (3)
Oregon
- Oregon Health and Science University - Portland
Utah
- Huntsman Cancer Institute at University of Utah - Salt Lake City
Washington
- Fred Hutchinson Cancer Research Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2021-01-12 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04409639
The ClinicalTrials.gov registry entry for NCT04409639 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 161-participant average among 6 other Chronic Myelomonocytic Leukemia (CMML) trials with a reported enrollment target (82% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Myelomonocytic Leukemia (CMML) appearing as the primary indexed condition, and to 1 intervention - of which Cobimetinib is the first listed.
NCT04409639 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Oregon, Utah, Washington.
Frequently Asked Questions
What is clinical trial NCT04409639 about?
NCT04409639 is a clinical study titled "Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations". This is an open-label, nonrandomized phase 2 trial to assess the efficacy of cobimetinib in RAS pathway activated CMML. All eligible patients will be treated daily with cobimetinib in 28-day cycles. Cobimetinib will be administered for three weeks followed by a one week break prior to the start of ...
What is the current status of trial NCT04409639?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2021-01-12. Estimated completion is 2026-08.
What conditions does trial NCT04409639 study?
This clinical trial studies the following conditions: Chronic Myelomonocytic Leukemia (CMML).
What interventions are being tested in trial NCT04409639?
The interventions under investigation include: Cobimetinib (DRUG).
Who is sponsoring clinical trial NCT04409639?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04409639 being conducted?
This trial has 3 study locations across Oregon, Utah, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelomonocytic Leukemia (CMML)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
RECRUITING · Phase 1
-
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
RECRUITING · Phase 1
-
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
RECRUITING · Phase 1
-
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
ACTIVE NOT RECRUITING · Phase 1
-
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.